Drotaverine

Drotaverine

File:Drotaverine.svg
Systematic (IUPAC) name
(Z)-1-(3,4-diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline
Clinical data
Routes of administration	Oral, intravenous
Pharmacokinetic data
Bioavailability	Highly variable
Protein binding	80 to 95%
Metabolism	Hepatic
Biological half-life	7 to 12 hours
Excretion	Fecal and renal
Identifiers
CAS Number	985-12-6
ATC code	A03AD02 (WHO)
PubChem	CID 1712095
Chemical data
Formula	C24H31NO4
Molar mass	397.507 g/mol[[]]

Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been shown to possess dose-dependant analgesic effects in animal models. One small study has shown drotaverine to be eliminated mainly non-renally.

A few small 2003 studies found drotaverine to be nearly 80% effective in treating renal colic. It has also been studied in accelerating labor by speeding up cervical dilation, but the results have been conflicting. Drotaverine has been shown to be effective in managing pain during hysteroscopy and endometrial biopsy when administered together with mefenamic acid. IBS patients presenting with predominant diarrhea are more likely to benefit from Buscopan. Drotaverin has also been tested in combination with rimantadine for antiviral activity against A and B type influenza. Drotaverin has an adverse effects frequency of 0.9%, side effects being relatively uncommon.

Drotaverine in sold under brand name No-Spa (Chinoin Pharmaceutical and Chemical Works, Hungary, a member of the Sanofi-Aventis).

References

pl:Drotaweryna ru:Дротаверин